The Biogen Inc., headquarters is pictured on March 11, 2020, in Cambridge, Mass. Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments. The Alzheimer’s treatment developer said Friday, July 28, 2023, it will pay $172.50 in cash for each share of Reata in a deal it expects to close by the end of this year. (AP Photo/Steven Senne, File)
Featured Photo Galleries
